 PARIS and CAMBRIDGE, Mass., July 19, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, Biophytis or the Company, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, announces that the judge in charge of overseeing judgements execution has rendered on July 16, 2021 a judgement in the proceedings between Biophytis and Negma Group Ltd. Negma. 